Inactive Instrument

BioHemp International, Inc. Stock Other OTC

BKIT

US09076B1052

Chart BioHemp International, Inc.

Duration

Period

Style

Dynamic Chart

Latest news about BioHemp International, Inc.

Biohemp International, Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019	19-07-15	CI
Biohemp International, Inc. Enters Agreement with American Premium Water Corporation to White Label Cannabidiol Infused Water Utilizing HIPH’s Proprietary Hydro Nano Technology	19-07-11	CI
BioHemp International, Inc. Appoints Ryan Fishoff as Lead Advisor to the Company	19-06-24	CI
Blake Insomnia Therapeutics, Inc. has Changed its Name to BioHemp International, Inc	19-06-18	CI
Blake Insomnia Therapeutics, Inc. Announces Management Changes	19-05-17	CI
Blake Insomnia Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended February 28, 2019	19-04-23	CI
Blake Insomnia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2018	19-02-27	CI
Blake Insomnia Therapeutics, Inc. will Change its Ticker to BKIT from BKITD	18-11-26	CI
Blake Insomnia Therapeutics, Inc. Announces Management Changes	18-03-12	CI
Blake Insomnia Therapeutics, Inc. announced that it expects to receive $1 million in funding	17-09-05	CI
Blake Insomnia Therapeutics Inc. Announces Submitting Clinical Trial Application for Phase II Clinical Testing to Health Canada	17-08-25	CI
Blake Insomnia Therapeutics Appoints Morten Albrechtsen to its Board of Directors	17-06-16	CI
Blake Insomnia Therapeutics Inc. Announces Board Appointments	17-05-25	CI
Blake Insomnia Therapeutics, Inc. Appoints Eric Leire to its Board of Directors	17-05-09	CI
Blake Insomnia Therapeutics Inc. Announces Joint Venture with Sajo Consulting LLC	17-02-25	CI

More news

Press releases BioHemp International, Inc.

BioHemp International Provides Update on Current Status and its CBD Business Model	19-10-24	GL
BioHemp International, Inc. (OTC: BKIT) Acts in Response to SEC and OTC Trading Suspension	19-08-09	GL
BioHemp International (OTC: BKIT) Clarifies Recent 8-K - No Material Change in Share Structure	19-07-15	GL
Daniel Blum, CEO at BioHemp International (OTC: BKIT), discusses new position, CBD opportunities, and long-term company goals with Cannabis Hemp Wire	19-07-10	GL
BioHemp International, Inc. (OTC: BKIT) Announces Deal to Private Label Water From American Premium Water Corporation (OTC: HIPH)	19-07-08	GL

More press releases

Managers and Directors - BioHemp International, Inc.

Managers	Title	Age	Since
Daniel Blum CEO	Chief Executive Officer	35	19-05-14

Members of the board	Title	Age	Since
Daniel Blum CEO	Chief Executive Officer	35	19-05-14

More insiders

BioHemp International, Inc., formerly Blake Insomnia Therapeutics, Inc., is a development-stage pharmaceutical company. The Company operates as a provider of insomnia remedy. The Company is focused on developing its business plan for an insomnia medication known as Zleepax. Zleepax is a sleep aid with beta-blockers as an active agent. As of August 31, 2016, the Company had no revenues.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.42%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.83%	360B
MERCK & CO., INC.	+16.13%	321B
ABBVIE INC.	+8.61%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-9.29%	149B

Other Pharmaceuticals